Company Overview and News

Resignation of CEO may delay BIMB’s reorganisation

Yesterday, CGS-CIMB Research said Khairul’s(filepic) resignation could be negative for the group in the short term as its key initiatives and plans could be delayed or shelved.
5258 6139

KLCI remains under pressure as spectre of trade war hangs over global markets

2018-07-12 theedgemarkets
KUALA LUMPUR (July 12): The FBM KLCI remained presured at mid-morning today, tracking regional markets as market sentiment stayed tepid with the spectre of a U.S.-China trade war still hanging over global markets.
HLFBF 7073 PBLOF 7113 4065 BATS TPGVF 4162 1295 7153 2089 KLKBY 3867 6139 7668 HRGHY UPBMF 1082 5168 0131 TGLVY 5139 2445 5216 0026 0900 1899 5819

BIMB to restructure once dust settles at Tabung Haji

2018-06-20 theedgemarkets
BIMB Holdings Bhd will likely embark on a group restructuring next year at the earliest as it waits for the dust to settle at Lembaga Tabung Haji (TH) where there is currently a boardroom shake-up, sources say.
1155 1023 1015 5258 MLYBY 6139 MLYNF AMMHF BSMAF 1818 CIMDF

Takaful Malaysia converts its composite licence into single licences

KUALA LUMPUR: Syarikat Takaful Malaysia Bhd (STMB) has announced the conversion of its composite licence into single licences and splitting of the company into two entities to manage the operations of its family and general takaful businesses separately.

Trading ideas: Unisem, Globetronics, CMMT, Minetech, Takaful Malaysia

KUALA LUMPUR: JF Apex Research expects Unisem (M) Bhd , Globetronics Technology Bhd , CapitaLand Malaysia Mall Trust (CMMT), Minetech Resources Bhd and Syarikat Takaful Malaysia Bhd to attract trading interest today.
6139 7219 5180 7022 GBTKF

Syarikat Takaful shares rise after earnings beat expectations

KUALA LUMPUR: Syarikat Takaful Malaysia Bhd ’s (STM) shares rose 4% in Wednesday morning trading after the insurer beat earnings expectations.
6139 BSMAF 1818

Takaful Malaysia posts 23% higher earnings in Q1

KUALA LUMPUR: Syarikat Takaful Malaysia Bhd 's first quarter earnings ended March 31, 2018, came in 23% higher year-on-year at RM69.98mil versus RM56.75mil previously on higher contributions from its general takaful division. Operating revenue for the group for the quarter grew 13% or RM86.3mil to RM746.2mil due to higher sales generated by both the family takaful and general takaful businesses. On a segmental basis, the family takaful business posted a slight dip in contributions to RM324mil from RM327.

Maybank prepares to spin off, list insurance unit

Listing candidate: Customers using ATMs at Maybank headquarters. Maybank’s insurance unit Etiqa is estimated to be worth at least RM3.89bil.
1155 MLYBY 6139 MLYNF

Maybank preparing to spin off insurance unit, sources say

2018-04-18 themalaymailonline
A pedestrian walks past a Maybank Bhd bank branch in Jalan Medan Tunku, Kuala Lumpur January 4, 2018. — Picture by Firdaus LatifKUALA LUMPUR, April 18 — Malayan Banking Bhd (Maybank), Malaysia’s biggest bank, is preparing to spin off and list its Etiqa insurance arm on the local stock exchange, sources with knowledge of the matter said today.
1155 MLYBY 6139 MLYNF

CIMB Equities Research retains Add for Syarikat Takaful

KUALA LUMPUR: CIMB Equities Research retains its Add call on Syarikat Takaful Malaysia (STM)due to the improved contribution momentum for the general takaful business.

Short Position

THE sterling set of results announced by Etiqa Group Insurance & Takaful recently makes it candidate for a corporate exercise.
1155 5225 MLYBY 6139 6459 MLYNF Q0F IHHHF

Syarikat Takaful’s digital push

PETALING JAYA: Syarikat Takaful Malaysia Bhd (STMB), which has the highest return on equity among all government-linked companies, is upbeat the company’s digital strategy will help maintain its leadership in family takaful business and gain further strength in the general takaful segment.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...